nanomedicine-2017-keynote

8 / 9

Page 23
Notes:
Biol Med Case Rep 2017 | Volume 1 Issue 2
alliedacademies
November 06-07, 2017 | New Orleans, USA
Nanomedicine & Healthcare
Global Meet on
In our group, we explore a new generation of smart living
implants combining not only active therapeutics but also stem
cells, as a novel strategy to regenerate stabilized cartilage and
avoid prosthesis, by achieving regeneration of its subchondral
bone foundation, requirement which is failing today in the
clinic. In our group, a unique nanotechnology strategy is used to
entrap, protect, and stabilize therapeutic agents into polymer
coatings: Nanoreservoirs, covering nanofibres of implantable
nanofibrous membranes for bone and cartilage regeneration.
Upon contact with cells, therapeutic agents become available
through enzymatic degradation of the nanoreservoirs. As cells
grow, divide, and infiltrate deeper into the porous membrane,
they trigger slow and progressive release of therapeutic
agents that, in turn, stimulate further cell proliferation. The
nanoreservoirs technology enables to reduce the quantities of
required therapeutic agent (compared to soaked membranes
for instance) thereby reducing costs.
Speaker Biography
N Benkirane Jessel is Research Director and the Head of the “Osteoarticular and Dental
Regenerative Nanomedicine” laboratory, at INSERM (French National Institute for
Health and Medical Research), UMR 1109, Strasbourg, France. She was the Leader
of “Active Biomaterials and Tissue Engineering” team INSERM 977. She has received
her PhD from University Louis Pasteur, ULP, Strasbourg, France for the work on
Development of pseudopeptides as synthetic vaccines. Dr. Jessel (Benkirane) then
held a postdoctoral position in collaboration with the Institut Pasteur, Paris, France,
working on Immunotherapy HIV, and another Postdoctoral position on the application
of modified peptides as vaccines against FMDV (Plum Island Animal Disease Center,
ARS, USDA, Greenport, NY 11944-0848, USA). She joined the INSERM U595 in 2002
as a post-doc, and received the diploma to direct the research (HDR) in 2004. Dr.
Jessel got the permanent position (CR1) in the INSERM 595 laboratory in 2004 and
Research Director (DR2) position in the INSERM 977 and head of “active Biomaterials
and Tissue Engineering team from 2009 until 2012). Currently Research Director (DR1)
in the INSERM UMR 1109 (Osteoarticular and Dental Regenerative Nanomedicine”
and heads the team. Dr. Jessel possesses expertise in diverse fields of molecular and
cellular biology, immunochemistry, tissue engineering and biomedical engineering. In
the last 10 years, she focused her research on the bio-functionalization of multilayered
polyelectrolyte architectures with emphasis on the use of these architectures to induce
specific cellular responses and gain control over cell proliferation and differentiation.
Dr. Benkirane-Jessel have 138 publications (h index: 36) with peer-reviewed
publications in high impact factor journals (Proc. Nat. Acad. Sci. USA; Adv. Mater.;
Adv. Funct. Mater. Small; Nanoletters, Biomaterials, ACS Nano), 5 chapters reviews
and 5 international patents, she is a regular referee for a number of scientific journals
(Nature nanotechnology, Nature Materials, ACS nano, Biomaterials, Nanoletters…). She
is under the contract (Interface INSERM/Clinic 2008-2013) and she got also “Prime
d’Excellence Scientifique” from the INSERM, 2010-2014 and the PEDR from the
INSERM on 2016 for 4 years.
e:
N Benkirane Jessel
University of Strasbourg, France
Combined therapeutic medical device and stem cells for regenerative nanomedicine